FOLFIRINOX: различия между версиями
Перейти к навигации
Перейти к поиску
| [отпатрулированная версия] | [отпатрулированная версия] |
Содержимое удалено Содержимое добавлено
Нет описания правки |
|||
| Строка 1: | Строка 1: | ||
'''FOLFIRINOX''' is a [[chemotherapy regimen]] for treatment of advanced [[pancreatic cancer]]. It is made up of the following four drugs: |
|||
#REDIRECT [[Режимы химиотерапии]] |
|||
* FOL — [[folinic acid]] (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; |
|||
* F — [[fluorouracil]] (5-FU), a [[pyrimidine analog]] and antimetabolite which incorporates into the DNA molecule and stops [[DNA synthesis]]; |
|||
* IRIN — [[irinotecan]] (Camptosar), a [[topoisomerase]] inhibitor, which prevents DNA from uncoiling and duplicating; and |
|||
* OX — [[oxaliplatin]] (Eloxatin), a [[platinum-based antineoplastic]] agent, which inhibits [[DNA repair]] and/or DNA synthesis. |
|||
The regimen emerged in 2010 as a new treatment for patients with [[metastatic]] pancreatic cancer.<ref>{{cite journal |last1=Conroy |first1=T |last2=Gavoille |first2=C |last3=Samalin |first3=E |last4=Ychou |first4=M |last5=Ducreux |first5=M |title=The role of the FOLFIRINOX regimen for advanced pancreatic cancer |journal=Current Oncology Reports |year=2013 |volume=15 |issue=2 |pages=182–189 |doi=10.1007/s11912-012-0290-4 |pmid=23341367}}</ref><ref>{{cite journal |last1=Faris |first1=JE |last2=Blaszkowsky |first2=LS |last3=McDermott |first3=S |last4=Guimaraes |first4=AR |last5=Szymonifka |first5=J |last6=Huynh |first6=MA |last7=Ferrone |first7=CR |last8=Wargo |first8=JA |last9=Allen |first9=JN |last10=Dias |first10=LE |last11=Kwak |first11=EL |last12=Lillemoe |first12=KD |last13=Thayer |first13=SP |last14=Murphy |first14=JE |last15=Zhu |first15=AX |last16=Sahani |first16=DV |last17=Wo |first17=JY |last18=Clark |first18=JW |last19=Fernandez-del Castillo |first19=C |last20=Ryan |first20=DP |last21=Hong |first21=TS |displayauthors=8 |title=FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience |journal=Oncologist |year=2013 |volume=18 |issue=5 |pages=543–548 |doi=10.1634/theoncologist.2012-0435 |pmid=23657686 |pmc=3662845}}</ref><ref>{{cite web |title=FOLFIRINOX |publisher=Pancreatic Cancer Association |url=http://pancreaticcanceraction.org/pancreatic-cancer/treatment/chemotherapy/chemotherapy-drugs-treat-cancer/folfirinox/ |accessdate=September 6, 2013}}</ref> A 2011 study published in the ''New England Journal of Medicine'' found that FOLFIRINOX produced the longest improvement in survival ever seen in a phase III clinical trial of patients with advanced pancreatic cancer, with patients on the FOLFIRINOX treatment living approximately four months longer than patients receiving the standard [[gemcitabine]] treatment (11.1 months compared with 6.8 months).<ref name=cancer.gov>{{cite web |title=Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients |publisher=[[National Cancer Institute]] |url=http://www.cancer.gov/clinicaltrials/results/summary/2011/pancreatic-chemo0611 |accessdate=September 6, 2013}}</ref><ref>{{cite journal |last1=Conroy |first1=T |last2=Desseigne |first2=F |last3=Ychou |first3=M |last4=Bouché |first4=O |last5=Guimbaud |first5=R |last6=Bécouarn |first6=Y |last7=Adenis |first7=A |last8=Raoul |first8=JL |last9=Gourgou-Bourgade |first9=S |last10=de la Fouchardière |first10=C |last11=Bennouna |first11=J |last12=Bachet |first12=JB |last13=Khemissa-Akouz |first13=F |last14=Péré-Vergé |first14=D |last15=Delbaldo |first15=C |last16=Assenat |first16=E |last17=Chauffert |first17=B |last18=Michel |first18=P |last19=Montoto-Grillot |first19=C |last20=Ducreux |first20=M |author21=Groupe Tumeurs Digestives of Unicancer |author22=PRODIGE Intergroup |displayauthors=8 |title=FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer |journal=[[New England Journal of Medicine]] |year=2011 |volume=364 |issue=19 |pages=1817–1825 |doi=10.1056/nejmoa1011923 |pmid=21561347}}</ref> However, FOLFIRINOX is a potentially highly toxic combination of drugs with serious side effects, and only patients with good [[performance status]] are candidates for the regimen.<ref name=cancer.gov /><ref name=thota>{{cite journal|last1=Thota|first1=R|last2=Pauff|first2=JM|last3=Berlin|first3=JD|title=Treatment of metastatic pancreatic adenocarcinoma: a review.|journal=Oncology (Williston Park, N.Y.)|date=Jan 2014|volume=28|issue=1|pages=70–4|pmid=24683721}}</ref> |
|||
In 2013, the U.S. [[Food and Drug Administration]] approved [[protein-bound paclitaxel]] (also known as nabPaclitaxel, sold as Abraxane) as a less toxic—but perhaps less effective—alternative to FOLFIRINOX for treating late-stage pancreatic cancer. Differences in the trials, and the lack of a direct trial comparing the two regimens, made a final conclusion impossible up to 2013.<ref name=thota /> |
|||
== Смотрите также == |
|||
* [[FOLFIRI]] |
|||
* [[FOLFOX]] |
|||
== Примечания == |
|||
{{примечания}} |
|||
[[Категория:Режимы химиотерапии при раке поджелудочной железы]] |
|||
[[Категория:Режимы химиотерапии при колоректальном раке]] |
|||
Версия от 15:03, 19 сентября 2014
FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer. It is made up of the following four drugs:
- FOL — folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil;
- F — fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis;
- IRIN — irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and
- OX — oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.
The regimen emerged in 2010 as a new treatment for patients with metastatic pancreatic cancer.[1][2][3] A 2011 study published in the New England Journal of Medicine found that FOLFIRINOX produced the longest improvement in survival ever seen in a phase III clinical trial of patients with advanced pancreatic cancer, with patients on the FOLFIRINOX treatment living approximately four months longer than patients receiving the standard gemcitabine treatment (11.1 months compared with 6.8 months).[4][5] However, FOLFIRINOX is a potentially highly toxic combination of drugs with serious side effects, and only patients with good performance status are candidates for the regimen.[4][6]
In 2013, the U.S. Food and Drug Administration approved protein-bound paclitaxel (also known as nabPaclitaxel, sold as Abraxane) as a less toxic—but perhaps less effective—alternative to FOLFIRINOX for treating late-stage pancreatic cancer. Differences in the trials, and the lack of a direct trial comparing the two regimens, made a final conclusion impossible up to 2013.[6]
Смотрите также
Примечания
- ↑ Conroy, T; Gavoille, C; Samalin, E; Ychou, M; Ducreux, M (2013). "The role of the FOLFIRINOX regimen for advanced pancreatic cancer". Current Oncology Reports. 15 (2): 182—189. doi:10.1007/s11912-012-0290-4. PMID 23341367.
- ↑ Faris, JE; Blaszkowsky, LS; McDermott, S; Guimaraes, AR; Szymonifka, J; Huynh, MA; Ferrone, CR; Wargo, JA; Allen, JN; Dias, LE; Kwak, EL; Lillemoe, KD; Thayer, SP; Murphy, JE; Zhu, AX; Sahani, DV; Wo, JY; Clark, JW; Fernandez-del Castillo, C; Ryan, DP; Hong, TS (2013). "FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience". Oncologist. 18 (5): 543—548. doi:10.1634/theoncologist.2012-0435. PMC 3662845. PMID 23657686.
{{cite journal}}: Неизвестный параметр|displayauthors=игнорируется (|display-authors=предлагается) (справка) - ↑ FOLFIRINOX. Pancreatic Cancer Association. Дата обращения: 6 сентября 2013.
- ↑ 1 2 Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients. National Cancer Institute. Дата обращения: 6 сентября 2013.
- ↑ Conroy, T; Desseigne, F; Ychou, M; Bouché, O; Guimbaud, R; Bécouarn, Y; Adenis, A; Raoul, JL; Gourgou-Bourgade, S; de la Fouchardière, C; Bennouna, J; Bachet, JB; Khemissa-Akouz, F; Péré-Vergé, D; Delbaldo, C; Assenat, E; Chauffert, B; Michel, P; Montoto-Grillot, C; Ducreux, M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011). "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer". New England Journal of Medicine. 364 (19): 1817—1825. doi:10.1056/nejmoa1011923. PMID 21561347.
{{cite journal}}: Неизвестный параметр|displayauthors=игнорируется (|display-authors=предлагается) (справка) - ↑ 1 2 Thota, R; Pauff, JM; Berlin, JD (Jan 2014). "Treatment of metastatic pancreatic adenocarcinoma: a review". Oncology (Williston Park, N.Y.). 28 (1): 70—4. PMID 24683721.